Evidence map›Paper›PMID 27547850›Full record

ArticleEndocrinology2016

Functional and Molecular Adaptations of Enteroendocrine L-Cells in Male Obese Mice Are Associated With Preservation of Pancreatic α-Cell Function and Prevention of Hyperglycemia.

Rodolphe Dusaulcy, Sandra Handgraaf, Svetlana Skarupelova, Florian Visentin, Christian Vesin, Mounia Heddad-Masson, Frank Reimann, Fiona Gribble, Jacques Philippe, Yvan Gosmain

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Enteroendocrine System and Gut Barrier in Metabolic Disorders.International journal of molecular sciences · 2022
    Review
  10. The Enteroendocrine System in Obesity.Handbook of experimental pharmacology · 2022
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Reprogramming Cells to Make Insulin.Journal of the Endocrine Society · 2019
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Rodolphe DusaulcyMolecular Diabetes Laboratory (R.D., S.H., S.S., F.V., M.H.-M., J.P., Y.G.), Division of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospital/Diabetes Center/University of Geneva Medical School; and Department of Cell Physiology and Metabolism (C.V.), University of Geneva School of Medicine, 1211 Geneva, Switzerland; and Wellcome Trust/Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit (F.R., F.G.), University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
Sandra HandgraafMolecular Diabetes Laboratory (R.D., S.H., S.S., F.V., M.H.-M., J.P., Y.G.), Division of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospital/Diabetes Center/University of Geneva Medical School; and Department of Cell Physiology and Metabolism (C.V.), University of Geneva School of Medicine, 1211 Geneva, Switzerland; and Wellcome Trust/Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit (F.R., F.G.), University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
Svetlana SkarupelovaMolecular Diabetes Laboratory (R.D., S.H., S.S., F.V., M.H.-M., J.P., Y.G.), Division of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospital/Diabetes Center/University of Geneva Medical School; and Department of Cell Physiology and Metabolism (C.V.), University of Geneva School of Medicine, 1211 Geneva, Switzerland; and Wellcome Trust/Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit (F.R., F.G.), University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
Florian VisentinMolecular Diabetes Laboratory (R.D., S.H., S.S., F.V., M.H.-M., J.P., Y.G.), Division of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospital/Diabetes Center/University of Geneva Medical School; and Department of Cell Physiology and Metabolism (C.V.), University of Geneva School of Medicine, 1211 Geneva, Switzerland; and Wellcome Trust/Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit (F.R., F.G.), University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
Christian VesinMolecular Diabetes Laboratory (R.D., S.H., S.S., F.V., M.H.-M., J.P., Y.G.), Division of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospital/Diabetes Center/University of Geneva Medical School; and Department of Cell Physiology and Metabolism (C.V.), University of Geneva School of Medicine, 1211 Geneva, Switzerland; and Wellcome Trust/Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit (F.R., F.G.), University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
Mounia Heddad-MassonMolecular Diabetes Laboratory (R.D., S.H., S.S., F.V., M.H.-M., J.P., Y.G.), Division of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospital/Diabetes Center/University of Geneva Medical School; and Department of Cell Physiology and Metabolism (C.V.), University of Geneva School of Medicine, 1211 Geneva, Switzerland; and Wellcome Trust/Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit (F.R., F.G.), University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
Frank ReimannMolecular Diabetes Laboratory (R.D., S.H., S.S., F.V., M.H.-M., J.P., Y.G.), Division of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospital/Diabetes Center/University of Geneva Medical School; and Department of Cell Physiology and Metabolism (C.V.), University of Geneva School of Medicine, 1211 Geneva, Switzerland; and Wellcome Trust/Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit (F.R., F.G.), University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
Fiona GribbleMolecular Diabetes Laboratory (R.D., S.H., S.S., F.V., M.H.-M., J.P., Y.G.), Division of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospital/Diabetes Center/University of Geneva Medical School; and Department of Cell Physiology and Metabolism (C.V.), University of Geneva School of Medicine, 1211 Geneva, Switzerland; and Wellcome Trust/Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit (F.R., F.G.), University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
Jacques PhilippeMolecular Diabetes Laboratory (R.D., S.H., S.S., F.V., M.H.-M., J.P., Y.G.), Division of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospital/Diabetes Center/University of Geneva Medical School; and Department of Cell Physiology and Metabolism (C.V.), University of Geneva School of Medicine, 1211 Geneva, Switzerland; and Wellcome Trust/Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit (F.R., F.G.), University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
Yvan GosmainMolecular Diabetes Laboratory (R.D., S.H., S.S., F.V., M.H.-M., J.P., Y.G.), Division of Endocrinology, Diabetes, Hypertension and Nutrition, University Hospital/Diabetes Center/University of Geneva Medical School; and Department of Cell Physiology and Metabolism (C.V.), University of Geneva School of Medicine, 1211 Geneva, Switzerland; and Wellcome Trust/Medical Research Council Institute of Metabolic Science and Medical Research Council Metabolic Diseases Unit (F.R., F.G.), University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom.
Addenbrooke's Hospital · GBUniversity of Geneva · CHWellcome Trust · GB

Funding

Medical Research Council MC_UU_12012/3Wellcome Trust 106263
6 · The paper itself

Abstract

Glucose homeostasis depends on the coordinated secretion of glucagon, insulin, and Glucagon-like peptide (GLP)-1 by pancreas and intestine. Obesity, which is associated with an increased risk of developing insulin resistance and type 2 diabetes, affects the function of these organs. Here, we investigate the functional and molecular adaptations of proglucagon-producing cells in obese mice to better define their involvement in type 2 diabetes development. We used GLU-Venus transgenic male mice specifically expressing Venus fluorochrome in proglucagon-producing cells. Mice were subjected to 16 weeks of low-fat diet or high-fat diet (HFD) and then subdivided by measuring glycated hemoglobin (HbA1c) in 3 groups: low-fat diet mice and I-HFD (glucose-intolerant) mice with similar HbA1c and H-HFD (hyperglycemic) mice, which exhibited higher HbA1c. At 16 weeks, both HFD groups exhibited similar weight gain, hyperinsulinemia, and insulin resistance. However, I-HFD mice exhibited better glucose tolerance compared with H-HFD mice. I-HFD mice displayed functional and molecular adaptations of enteroendocrine L-cells resulting in increased intestinal GLP-1 biosynthesis and release as well as maintained pancreatic α- and β-cell functions. By contrast, H-HFD mice exhibited dysfunctional L, α- and β-cells with increased β- and L-cell numbers. Administration of the GLP-1R antagonist Exendin9-39 in I-HFD mice led to hyperglycemia and alterations of glucagon secretion without changes in insulin secretion. Our results highlight the cross-talk between islet and intestine endocrine cells and indicate that a compensatory adaptation of L-cell function in obesity plays an important role in preserving glucose homeostasis through the control of pancreatic α-cell functions.

Indexed as

AnimalsDiabetes Mellitus, Type 2Diet, High-FatEnteroendocrine CellsGlucagonGlucagon-Like Peptide 1Glucagon-Secreting CellsHyperglycemiaInsulin-Secreting CellsMaleMice, Inbred C57BLMice, TransgenicObesityPeptide FragmentsPhenotypeexendin (9-39)GlucagonGlucagon-Like Peptide 1Peptide Fragments

Identifiers

PMID27547850
PMCPMC7228810
OpenAlexW2508367408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.